COMP <GO>
MCFT vs TMO // EV/EBITDA & P/E VALUATION
MasterCraft Boat Holdings Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: MCFT 3
— TMO 9
▲ EV/EBITDA & P/E VALUATION LEADER: MCFT
LAST: $21.24 (+5.44%) • MKT CAP: $514.4M
valuation
24.1x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MCFT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MCFT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 9.30% | -2.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 24.1x | 30.4x | -6.30 | MCFT | /valuation <GO> |
| Free Cash Flow Yield | 5.13% | 2.40% | +2.73 | MCFT | /fcf-yield <GO> |
| Operating Margin | 4.00% | 17.40% | -13.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 2.50% | 15.10% | -12.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -11.80% | 3.90% | -15.70 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.65 | 4.50 | +2.15 | MCFT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.2 | 62.9 | -1.68 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.9x | 36.3x | +31.60 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $514.4M | $262.22B | -$261.70B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MCFT REV | TMO REV | MCFT GROSS % | TMO GROSS % | MCFT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $284.2M | $44.56B | 20.0% | — | $26.4M | $6.29B |
| FY 2024 | $322.4M | $42.88B | 22.2% | — | $2.0M | $7.27B |
| FY 2023 | $609.9M | $42.86B | — | — | $134.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MCFT // BETA —
TMO // BETA 0.94